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Abstract
Background: The World Health Organization recommends at least 3 annual antibiotic mass drug administrations (MDA)
where the prevalence of trachoma is .10% in children ages 1–9 years, with coverage at least at 80%. However, the
additional value of higher coverage targeted at children with multiple rounds is unknown.
Trial Design: 262 factorial community randomized, double blind, trial.
Trial methods: 32 communities with prevalence of trachoma $20% were randomized to: annual MDA aiming for coverage
of children between 80%–90% (usual target) versus aiming for coverage.90% (enhanced target); and to: MDA for three
years versus a rule of cessation of MDA early if the estimated prevalence of ocular C. trachomatis infection was less than 5%.
The primary outcome was the community prevalence of infection with C. trachomatis at 36 months.
Results: Over the trial’s course, no community met the MDA cessation rule, so all communities had the full 3 rounds of MDA.
At 36 months, there was no significant difference in the prevalence of infection, 4.0 versus 5.4 (mean adjusted
difference = 1.4%, 95% CI =21.0% to 3.8%), nor in the prevalence of trachoma, 6.1 versus 9.0 (mean adjusted
difference = 2.6%, 95% CI =20.3% to 5.3%) comparing the usual target to the enhanced target group. There was no
difference if analyzed using coverage as a continuous variable.
Conclusion: In communities that had pre-treatment prevalence of follicular trachoma of 20% or greater, there is no
evidence that MDA can be stopped before 3 annual rounds, even with high coverage. Increasing coverage in children above
90% does not appear to confer additional benefit.
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Introduction
Trachoma, caused by ocular Chlamydia trachomatis, is the leading
infectious cause of blindness world-wide [1]. In addition to the
heavy personal and societal burden inflicted by loss of vision, there
are significant economic impacts as well. The 3.8 million cases of
blindness and 5.3 million cases of low vision due to trachoma are
estimated to diminish productivity by $2.9 billion each year [2].
A multi-faceted strategy to control all phases of trachoma has
been endorsed by the World Health Organization (WHO),
consisting of Surgery (to repair lids distorted by trachoma
(trichiasis) in imminent danger of vision loss), Antibiotics (mass
drug (antibiotic) treatment (MDA) to reduce the community pool
of infection with Chlamydia trachomatis), Face washing (to reduce
transmission from ocular and nasal secretions), and Environmental
improvements (to interrupt transmission and prevent re-emer-
gence). Children, particularly pre-school age children, in tracho-
ma-endemic communities are the reservoir of infection and active
follicular trachoma [3–5].
The WHO has recommended at least three years of annual
MDA, with coverage targets of 80% of the population, followed by
an impact survey to guide continued MDA. The indication for
ongoing MDA is a prevalence of clinical follicular trachoma of
$10% in children ages 1 to 9 years. However, there are no data
on whether increasing coverage in children would result in more
rapid declines in infection. Recent data from Tanzania suggest
that with coverage less than 80%, more than seven years of annual
mass drug administration (MDA) might be needed to achieve the
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target of trachoma less than 5% [6]. On the other hand, one
round of MDA with high coverage in low prevalence communities
in The Gambia lowered the infection rate to virtually zero
although clinical signs of trachoma were still present [7]. Such data
suggest that in low prevalence communities, high coverage may
obviate the need for three annual rounds of MDA. In addition,
relying for cessation of treatment on clinical signs of trachoma may
result in unnecessary treatment of communities where infection
has been eliminated and only residual disease is present. Yet, in
some communities, even low rates of active trachoma are
associated with the presence of infection [8]. Research on the
optimal use of antibiotic for trachoma control, especially now that
MDA distribution may be integrated with other neglected tropical
diseases is urgently needed [9].
We hypothesized that increasing the coverage of MDA to
greater than 90% as monitored in children would result in more
rapid decline in infection and trachoma compared to usual
coverage, between 80–90%. Where communities achieved an
estimated prevalence of infection less than 5% in children ages #
five years (regardless of status of clinical signs), we hypothesized
that the community could cease mass treatment without re-
emergence. To test these hypotheses, we conducted a community-
randomized trial in Kongwa Tanzania.
Methods
Ethics Statement
All study procedure and protocols were approved by the Johns
Hopkins University Institutional Review Board and the National
Institute for Medical Research in Tanzania. Written informed
consent was obtained by parents on behalf of all child participants.
ClinicalTrials.gov ID#NCT00792922.
Overview
Communities were randomized 1:1:1:1 in a 262 factorial design
to two different coverage targets: 80%–90% (usual target) versus
.90% (enhanced target). They were also randomized to two
different annual MDA strategies: yearly mass treatment for 3 years
(usual care) versus yearly mass treatment each year if warranted by
the infection prevalence above 5%; otherwise, the MDA would
cease for communities in this arm and the community monitored
for re-emergent infection (cessation rule) [10].
Communities were randomly selected from all communities in
Kongwa district based on previous research or assessment
suggesting the prevalence of TF was 20% or greater. Within each
community, 100 children less than five years old were randomly
selected and surveyed for trachoma and infection at baseline and
new samples selected every six months for 36 months. Mass drug
administration was provided to each community annually, unless
the community was randomized to the cessation rule arm and the
prevalence of infection or trachoma fell to less than 5%. Our
working definition of the cessation rule was if zero children out of
100 in the sentinel sample at 6 months or 18 months had infection,
as determined by PCR, then the next round of MDA would not
occur. With a sample size of 100 children, finding no infection is
associated with an exact upper 95% confidence limit less than 5%.
The design of the trial is shown in Figure 1. By the 18 month
survey, no community in the arms randomized to the cessation
rule had achieved an estimated prevalence of infection less than
5%, so all communities proceeded to have three rounds of MDA.
Thus, for the final analyses, the main effect of the stopping rule
was not considered since no communities were stopped. Only the
main effect for the coverage arms was analyzed.
Communities
The eligibility criteria for communities in this trial were as
follows:
1. Communities were part of the Kongwa District in Tanzania
2. If the population estimate from the last Tanzania census for the
community was greater than 5,000 persons, the community
was not included as these were considered urban areas.
3. Based on initial assessment the community prevalence of
trachoma was estimated at 20% or higher
4. The community leadership agreed that the community could
participate.
We defined communities as the smallest population level for
implementation of services. Kongwa district is part of the National
Trachoma Control Program for Tanzania, so all communities
outside the trial were offered MDA if the prevalence of TF was
.10% in children ages 0–9 years.
Intervention
MDA consists of a single dose of azithromycin, 20 mg/kg up to
1 GM, offered to all residents of the community ages 6 months or
older. Infants under age 6 months are offered topical tetracycline.
MDA was carried out by a network of paid community treatment
assistants (CTAs) who were trained and supervised by Kongwa
Trachoma Project staff. These were the only staff that had access
to the randomization assignment of the community in order to
monitor coverage and plan for MDA cessation.
The census list of the community was used to monitor coverage,
and as each resident presented for treatment, treatment was
observed and recorded in the treatment log by the CTA. The
numbers of treatment days were scheduled depending on the tally
of coverage at the end of the first three days in each community.
For subsequent days, the CTAs were notified in advance of
persons who missed MDA, and were to go house to house to
provide treatment. If, after the first 3 days of MDA, the percentage
of children treated was between 80% and 90% for the one
coverage arm, or above 90% for the second coverage arm, then
Author Summary
The World Health Organization recommends at least 3
annual antibiotic mass drug administrations (MDA) where
the prevalence of trachoma is .10% in children ages 1–9
years, with coverage at least at 80%. However, the
additional value of higher coverage targeted at children
with multiple rounds is unknown. We randomized 32
communities in Kongwa, Tanzania, with starting preva-
lence estimated at.20% to four arms: annual MDA aiming
for coverage of children between 80%–90% (usual target)
versus aiming for coverage.90% (enhanced target); and
to: MDA for three years versus a rule of cessation of MDA
early if the estimated prevalence of ocular C. trachomatis
infection was less than 5%. After three rounds of MDA,
infection with C. trachomatis and trachoma had declined
significantly from baseline but no communities had
treatment stopped. There was no difference in infection
or in trachoma at three years comparing the usual
coverage communities to the enhanced coverage com-
munities. We conclude that in communities that had pre-
treatment prevalence of follicular trachoma of 20% or
greater, there is no evidence that MDA can be stopped
before 3 annual rounds, even with high coverage.
Increasing coverage in children above 90% does not
appear to confer additional benefit.
Azithromycin Coverage in Tanzania for Trachoma
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treatment for that community stopped. If treatment was below
target, then the staff supervisor scheduled subsequent days for the
community, with treatment to be held for another day until
coverage targets are met or all persons accounted for in the
Treatment log. All persons who presented for treatment were
treated, even if it meant higher than 90% coverage for
communities randomized to 80–90% coverage.
Treatment verification was undertaken after each round of
MDA by having a sample of five households per CTA re-visited by
a supervisor. Each person in the household was queried about
receiving treatment. Payment of TSH 1,000 per day for the CTA
($0.80) was contingent on achieving 80% agreement on coverage
of persons in the five households.
Outcome Measures
The primary outcome measures are the prevalence of C.
trachomatis infection, and the prevalence of follicular trachoma, at
the community level at the 36 months survey (last follow up
December 2011).
Randomization Scheme
Using a custom built SAS macro for constrained randomi-
zation, the 32 villages were randomly assigned on a 1:1:1:1 to
each arm of the trial. This approach reduces the likelihood of a
bad randomization outcome by constraining the randomization
by baseline trachoma prevalence as a co-variate [11], thus
ensuring balance in each arm. The study statistician had the
responsibility for generating the random assignment of com-
munities. After the village leadership had agreed the community
would participate, the census and survey completed, the random
assignment was provided to the project director in Tanzania. He
then informed the MDA implementation team immediately
prior to MDA.
For each survey, a custom built Access program (Microsoft
Office 2007) randomly selected from the most recent census a list
of 110 children ages 5 years and under. A random number was
assigned to each child and we used the first 110 lowest numbers.
Ten children were kept in reserve in case of the unavailability of a
child in the first 100 children sampled.
Sample Size Determination
Assuming a standard deviation of 0.05 within each arm, a
correlation of 0.5 between baseline and 36 month results, a figure
observed from previous studies, and no interaction between
factors, we estimate that a total of 32 communities provides greater
than 80% power for each main effect. Neither the assumption of
plausible variation in a possible interaction effect nor the
assumption of a beta distribution rather than a normal distribution
altered these estimates to any substantial degree. Although we
estimated that between 40% and 80% of communities randomized
to the cessation rule arms would cease MDA, in fact zero
communities ceased MDA. Thus, for the final analyses, 16 villages
were in the 80–90% coverage group and 16 villages were in the
.90% coverage group.
Figure 1. Flow of Communities in Kongwa district through the Trial.
doi:10.1371/journal.pntd.0002415.g001
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Masking
The survey teams who assessed trachoma were masked to the
allocation of the communities in each arm, as they were never
shown the allocation and communities were surveyed in no order
by treatment allocation. It was theoretically possible that if a
community had MDA stopped their allocation to the cessation
rule would be unmasked, but none of the communities were
stopped.
The laboratory at Johns Hopkins University received specimens
with labels that could not be linked to persons or study arms by lab
personnel, and these were processed for infection masked to
intervention. The results were reported only to the statistician and
data managers of her team. The community residents who
participated in the survey were not told the results of the
laboratory findings, since all were eligible to receive azithromycin.
Thus, the infection outcomes were double masked.
Study Methods
Census. In each of the 32 communities, a complete census of
all households was carried out starting in May 2008 until
December 2008. The census was updated yearly and new
households and new persons in existing households were recorded,
as well as households and persons who no longer resided in the
community were noted.
Surveys. Details of the surveys are described elsewhere [10],
but summarized as follows:
The 100 sentinel children presented for examination at a central
site. Written informed consent was obtained from the guardian
prior to the start of the examination. The trachoma grader, lid
flipper, and laboratory person were all gloved and changed gloves
between subjects to avoid field contamination. Both eyelids of the
child were everted and the tarsal conjunctiva graded for signs of
clinical trachoma, using the WHO simplified grading scheme [12].
On a random sample of sentinel children, ocular photographs of
the right eye were taken to determine drift in grading over time. A
swab to test for infection was taken of the right eye, using a Dacron
swab, stored dry and frozen until shipped to the International
Chlamydia laboratory at Johns Hopkins. A 5% sample of ‘‘air’’
control swabs were also taken to test for field and laboratory
contamination.
The specimens were processed using the Amplicor kit (Roche
Molecular systems, Pleasanton, CA) according to strict protocol,
outlined in the manufacturer’s kit directions. Each swab was eluted
by vortexing in Amplicor CT/NG lysis buffer in polypropylene
tubes, and then Amplicor specimen diluent was added. Two C.
Trachomatis positive and two C. trachomatis negative processing
controls were run with each batch of specimens. Samples whose
values in valid runs were $0.8 A450 were counted as positive, and
samples less than 0.2 A450 were considered negative. Samples for
which the result were equivocal ($0,2, ,0.8) were tested again; if
equivocal twice, they were left as equivocal and reported as not
positive in the analyses as no run equaled 0.8 or greater. Less than
0.1% of specimens were equivocal. The laboratory personnel were
masked to community and treatment assignment.
Baseline, 12 month, and 24 month surveys were carried out
prior to annual MDA.
Quality control. Trachoma assessment was monitored over
time using the field photographs, at least 50 per grader per visit.
These were graded after each survey by a senior grader (RB)
masked to the field grades and to the grades of the images by the
field graders. Agreement was assessed using Kappa statistic, and if
agreement fell below 0.6 for any survey, re-standardization was
instituted to bring agreement to acceptable levels. At no survey
was agreement less than 0.6
Field and laboratory contamination was monitored over time
using the field ‘‘air’’ controls, as well as internal laboratory controls
for each run. If any field control was positive, then immediate
investigation was undertaken to determine the source of contam-
ination, and specimens re-run if needed to confirm results. At the
baseline survey, the laboratory experienced contamination in the
initial processing of the specimens, and 76 specimens (23, 43, and
10 in each of three communities) out of 3200 could not be used.
There were no further losses due to contamination in the study.
Data quality, results of monitoring for quality of trachoma
assessment and laboratory assessment of infection, were presented
to a yearly meeting of the Data and Safety Monitoring Committee.
Statistical analyses. Because no community in the ‘‘stop-
ping rule’’ arm reached the pre-specified rule for ceasing MDA,
the analytic plan was based on the main effect of two coverage
arms, as follows:
The primary analyses were conducted on the intention-to-treat
principle (ITT); therefore, communities were analyzed according
to their coverage randomization assignment regardless of their
actual coverage level. We pre-specified that if there was no
difference in the ITT analyses, we would undertake analyses of
actual coverage and the relationship to infection and trachoma at
36 months.
We compared baseline community and other characteristics
that may be related to the prevalence of infection/follicular
trachoma prior to conducting further analyses, and any variables
unevenly distributed among groups was included in all multivar-
iate models to control for potential residual confounding.
Population characteristics were summarized at community level
and then summarized by group. The mean (SD) for each arm is
presented for each characteristic. The Kruskal-Wallis test was used
for comparison.
This trial had a pre-specified outcome of the prevalence at 36
months only, because usual program practice is to evaluate the
outcomes at 3 years post-baseline and it was felt that the difference
in coverage levels would be seen by three years. We modeled the
community-level prevalence at 3-years post first mass treatment on
a square root transformed scale. Ordinary least squares (OLS)
linear regression was used to model the square-root transformed
prevalence including independent variables for coverage arm and
baseline prevalence of infection/follicular trachoma.
We calculated the adjusted mean difference in prevalence of
infection/follicular trachoma by treatment arm at 36 months as
follows: 1) For each community, using the baseline observed
prevalence, treatment arm, and the parameters estimated from the
square root transformed model described above, we estimated the
predicted prevalence. 2) For each arm we average the estimated
prevalences; 3) The difference in the adjusted mean prevalence for
enhanced arm and the standard arm was then calculated. 4) In
order to derive the confidence intervals for the adjusted difference,
we repeated Steps 1 to 4 for 1000 bootstrap samples; 5) The
median of the adjusted mean differences and corresponding 2.5%
and 97.5% percentiles were reported.
Results
A comparison of baseline characteristics of each of the 4 groups
of communities showed no imbalances in population size,
percentage of households with no latrine, percentage more than
30 minutes from water, or average education of head of
household. Similar prevalence of follicular trachoma and C.
trachomatis infection were observed (Table 1). For the rest of the
analyses, we show only the coverage arms because none of the
communities stopped MDA during the study (Figure 1)
Azithromycin Coverage in Tanzania for Trachoma
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The treatment coverage at each of the three rounds of mass
drug administration was consistently greater in the enhanced
target group compared to the usual target group (Table 2). The
average difference between the two groups in terms of coverage
was never more than 6% (third round of mass treatment). All of
the communities in the usual target arm achieved coverage above
80% in children under age ten years in each of the three rounds.
Only at the one year treatment round did one village in the
enhanced target group have coverage below 90%.
The baseline prevalence of infection with C. trachomatis was not
different between the two coverage groups, 20.1% and 23.8%
respectively (Figure 2). There was a decline in infection from
baseline to 36 months in both the usual target group and the
enhanced coverage group. At 36 months (one year after the third
MDA), the prevalence of infection was 4.0% in the usual target
group and 5.4% in the enhanced target group, with an adjusted
difference of 1.4% (95% Confidence Interval (CI) =21.0% to
3.8%).
The prevalence of follicular trachoma by treatment group
showed a similar patter, with no difference between groups at
baseline, 30.4% and 30.9% in the usual target and enhanced
target group respectively (Figure 3). By 36 months, the trachoma
prevalence had fallen to 6.1% and 9.0% respectively, an adjusted
difference of 2.6% with 95% CI=2.3% to 5.3%.
Separate models of infection and trachoma at 36 months,
adjusted for baseline prevalence, showed no effect of being in the
enhanced target arm (Table 3). The prevalence of trachoma at
baseline predicted the prevalence of trachoma at 36 months, but
the prevalence of infection at baseline was not predictive of
infection at 36 months.
When analyzed as actual coverage, there was still no evidence
that increasing coverage in children resulted in lower infection or
trachoma prevalence at 36 months (Table 4). If the variable of
average percentage coverage over the three rounds was replaced
with a variable of percentage coverage at the last round of mass
treatment, there was still no evidence for a significant decrease in
infection or trachoma with increasing coverage at 36 months (data
not shown).
There were no serious adverse events reported in either arm.
Discussion
This community based, randomized trial had two major
findings: first, there was no evidence of benefit to increasing mass
drug administration coverage of children ages under ten years
above 90%, compared to targeting coverage between 80–90%.
The analyses repeated on actual coverage found no benefit per
unit increase in coverage either. Second, that if the baseline
prevalence of trachoma in communities are estimated at 20% or
greater, two years of annual MDA were insufficient to decrease
infection in any community below an estimate of 5% and at least
three annual rounds will be necessary even with high coverage.
There may be at least two possible reasons for the first finding.
With coverage this high in children, there were very few children
who were not treated at least once after three MDAs. In a study in
these communities of persistent non- participation in MDA,
Ssemanda et al found that only 2% of households contained
children who did not participate in 2 MDAs [13]. By the third
round of MDA, there may be little benefit to the extra effort
required to achieve over 90% coverage. This supposition has
Table 1. Baseline characteristics by randomization group.
Characteristic Statistic Allocation (8 communities per arm)
p-value
Kruskal-Wallis
80–90% coverage
3 annual MDA
.90% coverage
3 annual MDA
80–90% coverage
Cessation rule
.90% coverage
Cessation rule
Population size Mean (SD) 1456 (243) 1316 (465) 1379 (481) 1678 (472) 0.42
Household head years
of education:
Mean (SD) 3.4 (0.7) 3.2 (1.0) 3.2 (1.0) 3.2 (0.9) 0.79
% houses .30 minutes
from water
Mean (SD) 67.2 (28.0) 80.9 (24.2) 84.1 (14.9) 71.9 (26.3) 0.53
% houses with latrine Mean (SD) 72.0 (10.8) 62.9 (23.4) 62.2 (10.7) 62.0 (20.3) 0.58
Prevalence of TF in
children 0–,5 years
Mean (SD) 30.3 (13.5) 30.7 (16.3) 30.5 (10.4) 31.1 (9.5) 0.99
Prevalence of C. trachomatis
in children 0–,5 years
Mean (SD) 17.8 (10.3) 24.6 (12.4) 22.4 (23.3) 23.0 (11.2) 0.55
Data are summary statistics generated from community level summary measures.
doi:10.1371/journal.pntd.0002415.t001
Table 2. Treatment coverage in children under 10 years of age by randomization group.
Time Statistic Allocation (16 communities per arm) p-value Wilcoxon
80–90% .90%l
Baseline Mean 6SD 90.865.4 96.662.3 0.001
One Year Mean 6 SD 87.765.6 92.564.0 0.02
Two Years Mean 6 SD 86.764.3 92. 762.5 0.001
doi:10.1371/journal.pntd.0002415.t002
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supporting evidence with the rapid fall in infection by 36 months
in both arms of the trial. Trachoma at baseline in these
communities averaged 30%, with 22% infection. By three years
and three rounds of MDA, infection averaged 4.7% and trachoma
fell to an average of 7.6%. The trajectory suggests that just a few
more rounds of MDA would be needed to decrease trachoma
below 5% and even eliminate infection, fewer annual rounds than
suggested by other work in Tanzania where coverage was
estimated at less than 75% [6].
Another possible reason is that the difference in coverage in the
enhanced target versus the usual target groups was relative small.
The coverage in children in the usual target group was high, 90%,
88%, and 87% respectively for the three rounds. While some
communities were lower, no community had MDA coverage in
children below 80%, by design. The enhanced target group had
significantly higher coverage, but the largest difference was in the
third round with average coverage of 93% compared to the usual
care group with average coverage of 87%. However, even
adjusting for slightly higher rates of infection in the enhanced
coverage group, there was no survey where the enhanced coverage
group had a point estimate that was lower infection or trachoma
compared to the usual coverage group. When the analyses were
repeated using actual coverage in the communities, where the
range was greater, there was no apparent effect of increasing
coverage on infection or trachoma. The data appear to be more
consistent with an absence of an effect of enhanced coverage than
failure to detect a difference.
It is unlikely that the intervention was carried out improperly in
either arm of the trial. Treatment verification consistently showed
high agreement between recorded treatment and personal history
of recipients. Trachoma and infection fell over time consistent with
good coverage in children as reported from studies elsewhere in
other high prevalence villages [14,15].
The fact that we did not stop MDA in any of the communities
randomized to the cessation rule, even with high coverage,
provides support for the WHO guideline that suggest 3 rounds of
MDA before re-assessing the impact, at least for communities with
baseline prevalence above 20%. We had expected that with high
coverage, communities would reach our pre-specified target of
zero cases of infection in 100 sentinel children before the third
round of MDA. This did not happen when the starting
prevalences of infection in the communities were, on average,
22%. Our experience was different than the experience with high
coverage in small communities in Ethiopia, where after a single
round of high coverage, infection fell from 50% to less than 5% at
6 months and after a second round at 6 months, disappeared [15].
Other studies in The Gambia and in a low prevalence community
Figure 3. Prevalence of Follicular Trachoma (TF) over time by
Coverage Arm.
doi:10.1371/journal.pntd.0002415.g003
Table 3. Impact of enhanced target coverage on prevalence* of C. trachomatis infection and follicular trachoma at 36 months.
Variable Parameter Estimate (b) 95% Confidence Intervals
Predicting infection
Enhanced coverage group 0.034 20.028, 0.096
Baseline C. trachomatis prevalence (square root) 20.024 20.276, 0.228
Predicting clinical trachoma
Enhanced coverage group 0.050 20.007, 0.106
Baseline TF prevalence (square root) 0.357 0.107, 0.608
*Squared root transformation.
doi:10.1371/journal.pntd.0002415.t003
Figure 2. Prevalence of C. trachomatis Infection over time by
Coverage Arm.
doi:10.1371/journal.pntd.0002415.g002
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in Tanzania reported that one to two annual rounds was sufficient
to eliminate infection [7,16], but these communities started with
low levels of infection. A recent study from Ethiopia noted that
annual treatment with high coverage reduced infection from 42%
in children ages 0–9 years to 1.9% after four rounds of annual
MDA, which is more consistent with the trajectory of our observed
decline [17]. In that study, 5 of the 12 communities had no
infection at 36 months, but with on average only 50 sentinel
children per community, the possibility of infection as high as 5%
could not be ruled out.
In summary, a community randomized clinical trial comparing
high coverage (80–90%) in children with antibiotic for trachoma
to very high coverage (.90%) found no difference in infection or
trachoma rates after three annual rounds of MDA. The results
suggest that aiming for at least 80% coverage of children in
trachoma endemic communities is reasonable, and there is no
advantage to expending resources to push for even higher
coverage. When treating communities with 20% or greater
prevalence of trachoma at baseline, at least 3 rounds of MDA
will be needed before infection drops confidently below 5%.
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